Cargando…

Sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: A systematic review and meta-analysis

BACKGROUND: To assess the safety and efficacy of sorafenib and sunitinib as first-line treatments for metastatic renal cell carcinoma (mRCC), to provide evidence-based support for clinical decision-making regarding rational drug use. METHODS: Until May 10, 2023, a comprehensive search was conducted...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dailong, Wan, Sha, Li, Wanqiang, Cheng, Chunlai, Xu, Lu, Gu, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10489528/
https://www.ncbi.nlm.nih.gov/pubmed/37682147
http://dx.doi.org/10.1097/MD.0000000000034983
_version_ 1785103666674401280
author Li, Dailong
Wan, Sha
Li, Wanqiang
Cheng, Chunlai
Xu, Lu
Gu, Peng
author_facet Li, Dailong
Wan, Sha
Li, Wanqiang
Cheng, Chunlai
Xu, Lu
Gu, Peng
author_sort Li, Dailong
collection PubMed
description BACKGROUND: To assess the safety and efficacy of sorafenib and sunitinib as first-line treatments for metastatic renal cell carcinoma (mRCC), to provide evidence-based support for clinical decision-making regarding rational drug use. METHODS: Until May 10, 2023, a comprehensive search was conducted across PubMed, EMBASE, Cochrane Library, ClinicalTrials.gov, China National Knowledge Infrastructure, and Wanfang databases to identify clinical studies comparing sorafenib with sunitinib as first-line treatment for mRCC. The literature was screened, data extracted, and quality evaluated independently by 2 researchers. Meta-analysis was conducted using Revman5.4 software. RESULTS: A total of 3741 patients were enrolled in 20 studies. The meta-analysis results indicated that there were no significant differences in the 2- and 5-year progression-free survival (PFS) and overall survival (OS) rates between the sorafenib and sunitinib groups (P > .05). The disease control rate (DCR) was comparable between the 2 groups (P > .05), while the objective response rate (ORR) was higher in the sunitinib group (P = .03). However, subgroup analysis revealed no significant differences in ORR, DCR, 2- and 5-year PFS, and OS rates between sorafenib and sunitinib among both Asian populations as well as European and American populations (P > .05). In terms of drug-related adverse events, the incidence of grade ≥ 3 hypertension, leukopenia, neutropenia, thrombocytopenia, anemia, nausea and vomiting were significantly lower in the sorafenib group compared to the sunitinib group (P < .05). CONCLUSION: In the first-line treatment of mRCC, sorafenib exhibits comparable efficacy to sunitinib but with lower toxicity.
format Online
Article
Text
id pubmed-10489528
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104895282023-09-09 Sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: A systematic review and meta-analysis Li, Dailong Wan, Sha Li, Wanqiang Cheng, Chunlai Xu, Lu Gu, Peng Medicine (Baltimore) 5700 BACKGROUND: To assess the safety and efficacy of sorafenib and sunitinib as first-line treatments for metastatic renal cell carcinoma (mRCC), to provide evidence-based support for clinical decision-making regarding rational drug use. METHODS: Until May 10, 2023, a comprehensive search was conducted across PubMed, EMBASE, Cochrane Library, ClinicalTrials.gov, China National Knowledge Infrastructure, and Wanfang databases to identify clinical studies comparing sorafenib with sunitinib as first-line treatment for mRCC. The literature was screened, data extracted, and quality evaluated independently by 2 researchers. Meta-analysis was conducted using Revman5.4 software. RESULTS: A total of 3741 patients were enrolled in 20 studies. The meta-analysis results indicated that there were no significant differences in the 2- and 5-year progression-free survival (PFS) and overall survival (OS) rates between the sorafenib and sunitinib groups (P > .05). The disease control rate (DCR) was comparable between the 2 groups (P > .05), while the objective response rate (ORR) was higher in the sunitinib group (P = .03). However, subgroup analysis revealed no significant differences in ORR, DCR, 2- and 5-year PFS, and OS rates between sorafenib and sunitinib among both Asian populations as well as European and American populations (P > .05). In terms of drug-related adverse events, the incidence of grade ≥ 3 hypertension, leukopenia, neutropenia, thrombocytopenia, anemia, nausea and vomiting were significantly lower in the sorafenib group compared to the sunitinib group (P < .05). CONCLUSION: In the first-line treatment of mRCC, sorafenib exhibits comparable efficacy to sunitinib but with lower toxicity. Lippincott Williams & Wilkins 2023-09-08 /pmc/articles/PMC10489528/ /pubmed/37682147 http://dx.doi.org/10.1097/MD.0000000000034983 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle 5700
Li, Dailong
Wan, Sha
Li, Wanqiang
Cheng, Chunlai
Xu, Lu
Gu, Peng
Sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: A systematic review and meta-analysis
title Sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: A systematic review and meta-analysis
title_full Sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: A systematic review and meta-analysis
title_fullStr Sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: A systematic review and meta-analysis
title_full_unstemmed Sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: A systematic review and meta-analysis
title_short Sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: A systematic review and meta-analysis
title_sort sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: a systematic review and meta-analysis
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10489528/
https://www.ncbi.nlm.nih.gov/pubmed/37682147
http://dx.doi.org/10.1097/MD.0000000000034983
work_keys_str_mv AT lidailong sorafenibexhibitslowertoxicityandcomparableefficacytosunitinibasafirstlinetreatmentformetastaticrenalcellcarcinomaasystematicreviewandmetaanalysis
AT wansha sorafenibexhibitslowertoxicityandcomparableefficacytosunitinibasafirstlinetreatmentformetastaticrenalcellcarcinomaasystematicreviewandmetaanalysis
AT liwanqiang sorafenibexhibitslowertoxicityandcomparableefficacytosunitinibasafirstlinetreatmentformetastaticrenalcellcarcinomaasystematicreviewandmetaanalysis
AT chengchunlai sorafenibexhibitslowertoxicityandcomparableefficacytosunitinibasafirstlinetreatmentformetastaticrenalcellcarcinomaasystematicreviewandmetaanalysis
AT xulu sorafenibexhibitslowertoxicityandcomparableefficacytosunitinibasafirstlinetreatmentformetastaticrenalcellcarcinomaasystematicreviewandmetaanalysis
AT gupeng sorafenibexhibitslowertoxicityandcomparableefficacytosunitinibasafirstlinetreatmentformetastaticrenalcellcarcinomaasystematicreviewandmetaanalysis